Collplant Holdings (CLGN) AI Stock Analysis

• Market Cap: $21.24M
• Dividend Yield: N/A
• Average Volume (3M): 29.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: 280.77%
• EPS Growth: 32.82%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 12,716,014
• 10 Day Avg. Volume: 15,198
• 30 Day Avg. Volume: 29,183
• PEG Ratio: -0.02
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 80.07
• P/FCF Ratio: -2.83
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 11.56
• Enterprise Value/Gross Profit: 46.01
• Enterprise Value/Ebitda: -2.59
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $1.50 ▼(-0.66% Downside)

The score is held down primarily by weak financial performance (heavy losses and persistent cash burn despite a TTM revenue rebound) and bearish technical trends (below major moving averages with a negative MACD). Valuation is only mildly supportive since the negative P/E reflects unprofitable operations and there is no dividend yield.

Positive Factors

Strategic Partnerships

Collaboration with a major player like AbbVie can enhance product development and market reach, providing a durable competitive advantage.

Innovative Product Development

Superior product performance in studies positions CollPlant's bioink as a leader in tissue engineering, supporting long-term growth potential.

Market Expansion

Expanding distribution capabilities in North America enhances market presence and logistical efficiency, supporting revenue growth.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in sustaining sales, impacting financial stability and long-term viability.

Negative Cash Flow

Negative cash flow limits the company's ability to fund operations and invest in growth, posing a risk to financial health.

Workforce Reduction

Workforce reduction may indicate cost pressures and operational challenges, potentially affecting morale and productivity.

Collplant Holdings Business Overview & Revenue Model

Company Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

How the Company Makes Money

CollPlant generates revenue through the commercialization of its proprietary collagen products and technologies. The company's primary revenue streams include direct sales of its wound healing and tissue regeneration products to hospitals, clinics, and healthcare providers, as well as licensing agreements with strategic partners in the medical and aesthetic industries. Significant partnerships with key players in the biotechnology and medical device sectors enhance its market reach and facilitate product development. Additionally, CollPlant may receive milestone payments and royalties from its partners based on the commercial success of collaborative products, further contributing to its earnings.

Collplant Holdings Financial Statement Overview

Summary

Collplant Holdings is facing severe financial challenges with significant revenue and cash flow declines, negative profit margins, and shrinking assets and equity. Despite low debt levels, the company's ability to generate revenue and positive cash flow is a major concern.

Income Statement

Collplant Holdings has experienced significant revenue volatility, with a notable revenue decline from $10.96 million in 2023 to $0.515 million in 2024. The company is struggling with negative margins, including a gross profit margin of -215% and a net profit margin of -3226% in 2024. Despite a brief profitable period in 2021, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio remains low at 0.23 in 2024, reflecting a conservative leverage approach. However, stockholders' equity has decreased significantly, and the equity ratio has dropped from 88% in 2021 to 72% in 2024, indicating weakening financial stability. The company's asset base has also shrunk considerably over the same period.

Cash Flow

Collplant Holdings' free cash flow has deteriorated significantly, with a negative free cash flow of $14.58 million in 2024, compared to $3.72 million in 2023. The operating cash flow to net income ratio and free cash flow to net income ratio are both negative, showing a lack of cash flow generation. Despite previous years of positive cash flow from financing activities, the company's cash reserves are depleting.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.48M	515.00K	10.96M	299.00K	15.64M	6.14M
Gross Profit	622.00K	-2.15M	7.87M	-1.18M	13.64M	2.68M
EBITDA	-11.05M	-15.55M	-5.91M	-15.81M	1.05M	-5.08M
Net Income	-12.16M	-16.61M	-7.02M	-16.93M	237.00K	-5.77M
Balance Sheet
Total Assets	14.09M	18.71M	34.13M	37.77M	51.22M	10.84M
Cash, Cash Equivalents and Short-Term Investments	8.55M	11.91M	26.67M	29.65M	43.30M	3.33M
Total Debt	2.94M	3.08M	3.16M	2.91M	3.61M	3.39M
Total Liabilities	4.78M	5.25M	5.79M	5.49M	6.10M	6.36M
Stockholders Equity	9.30M	13.46M	28.34M	32.28M	45.12M	4.48M
Cash Flow
Free Cash Flow	-10.02M	-14.58M	-3.72M	-14.97M	1.07M	-4.89M
Operating Cash Flow	-9.95M	-14.09M	-2.76M	-13.70M	2.50M	-4.45M
Investing Cash Flow	-70.00K	-539.00K	-1.16M	28.92M	-31.56M	-519.00K
Financing Cash Flow	3.10M	9.00K	1.11M	1.87M	38.76M	4.46M

Collplant Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Neutral. The current price of 1.51 is above the 20-day moving average (MA) of 1.48, below the 50-day MA of 1.83, and below the 200-day MA of 2.14, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 53.40 is Neutral, neither overbought nor oversold. The STOCH value of 71.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLGN.

Collplant Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PYPD	56 Neutral	$68.99M	-1.46	-390.53%	―	―	61.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DARE	50 Neutral	$29.01M	-4.60	―	―	―	―
SABS	50 Neutral	$190.43M	-1.30	-21.16%	―	-92.42%	62.37%
PASG	49 Neutral	$47.30M	-1.05	-87.18%	―	―	38.42%
CLGN	46 Neutral	$21.24M	-1.63	-92.74%	―	280.77%	32.82%
NRSN	44 Neutral	$31.78M	-1.83	―	―	―	31.09%

Collplant Holdings Corporate Events

CollPlant Shareholders Approve All Proposals at December 31, 2025 General Meeting

On December 31, 2025, CollPlant Biotechnologies Ltd. held its Annual and Extraordinary General Meeting of Shareholders in which investors approved all four proposals on the agenda, each receiving the requisite majority. The shareholder approvals, which followed the company’s November 26, 2025 notice convening the meeting, clear the way for CollPlant to implement its proposed corporate and governance actions without opposition, supporting continuity in management’s strategic plans and regulatory compliance as a foreign private issuer.

The most recent analyst rating on (CLGN) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

CollPlant Biotechnologies Announces Annual and Extraordinary General Meeting for December 2025

On November 26, 2025, CollPlant Biotechnologies Ltd. announced that it will hold its annual and extraordinary general meeting of shareholders on December 31, 2025, in Tel-Aviv, Israel. The meeting will address several key proposals, including the re-election of board members, re-appointment of auditors, renewal of the compensation policy for directors and officers, and the appointment of CEO Yehiel Tal as interim Chairman of the Board. The outcomes of this meeting could influence the company’s governance and strategic direction, impacting stakeholders and potentially affecting its market position.

The most recent analyst rating on (CLGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

CollPlant Biotechnologies Expands North American Operations and Reports Q3 2025 Results

CollPlant Biotechnologies reported its third-quarter financial results for 2025, highlighting significant advancements and strategic initiatives. The company announced the expansion of its rhCollagen and BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance its market presence. Recent developments include a collaboration with Mayo Clinic to create a humanized bioprinted skin model, and a comparative study showing its bioink, Collink.3D™, outperformed a leading extracellular matrix in tissue formation. Additionally, CollPlant is implementing cost-reduction measures and prioritizing its collaboration with AbbVie and the development of its dermal filler product. The company is also expanding its international distribution network for its tendon-repair product, Vergenix™ STR, into new markets.

The most recent analyst rating on (CLGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

CollPlant Expands rhCollagen Distribution in North America

On October 27, 2025, CollPlant Biotechnologies announced the expansion of its distribution capabilities in North America through a new partnership with a U.S.-based logistics center. This new logistics hub, which is set to become operational within the quarter, will enhance the distribution of CollPlant’s rhCollagen and BioInk products in the U.S. and Canada. The center is equipped with advanced infrastructure to ensure efficient and secure distribution, reflecting CollPlant’s commitment to the North American market and its strategy to improve logistical efficiency and customer service.

The most recent analyst rating on (CLGN) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

CollPlant’s BioInk Outperforms Matrigel in Technion Study

On October 20, 2025, CollPlant Biotechnologies announced positive results from a study conducted by the Technion – Israel Institute of Technology, which demonstrated that its rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation. This suggests that Collink.3D™ could serve as a next-generation, animal-free extracellular matrix for advanced tissue engineering and research applications, potentially impacting the market for basement membrane matrices, which is projected to grow significantly by 2031.

The most recent analyst rating on (CLGN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

CollPlant and Mayo Clinic Unveil Humanized 3D Bioprinted Skin Model

On October 16, 2025, CollPlant Biotechnologies announced the development of a first-of-its-kind fully humanized 3D bioprinted human skin model by Mayo Clinic researchers, utilizing CollPlant’s rhCollagen-based bioink. This model, which serves as an alternative to animal testing, has significant implications for cosmetic and pharmaceutical testing, disease modeling, and drug development, offering a sustainable and ethical solution while advancing regenerative medicine.

The most recent analyst rating on (CLGN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.